Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 2; no. 2; pp. 121 - 130
• Main Authors: Koppel, Jeremy, Jimenez, Heidy, Adrien, Leslie, Greenwald, Blaine S, Marambaud, Philippe, Cinamon, Ezra, Davies, Peter
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2016; John Wiley & Sons, Inc; Elsevier
• Subjects: Alzheimer's disease; AMPK; Antipsychotics; Dementia; Dopamine; Haloperidol; Kinases; Medical research; Neurology; Older people; Other; Pathology; Psychotropic drugs; Tau; Antipsychotics; AMPK; Tau; Dopamine; Haloperidol; Alzheimer's disease
• ISSN: 2352-8737; 2352-8737
• DOI: 10.1016/j.trci.2016.05.003

Introduction The use of antipsychotic medications in Alzheimer's disease has been associated with an increased risk of mortality in clinical trials. However, an older postmortem literature suggests that those with schizophrenia treated in an era of exclusively conventional antipsychotic medications had a surprisingly low incidence of tau pathology. No previously published studies have investigated the impact of conventional antipsychotic exposure on tau outcomes in a tau mouse model of AD. Methods In two experiments, transgenic rTg (tauP301L) 4510 tau mice were treated with either haloperidol or vehicle and phosphotau epitopes were quantified using high-sensitivity tau ELISA. Results After treatments of 2 and 6 week's duration, mice treated with haloperidol evidenced a significant reduction in tau phosphorylation associated with an inactivation of the tau kinase AMPK. Discussion The data suggest that D2 receptor blockade reduces tau phosphorylation in vivo. Future studies are necessary to investigate the impact of this reduction on tau neuropathology.